Artigo

Case series: psoriasis in solid organ transplant patients and immunobiological agents

André Vicente Esteves de Carvalho

Anais Brasileiros de Dermatologia, v. 98, n. 5, p. 678-688, 2023.

Motivo: Produção Corpo Clínico

Setor HMV: Clínica Médica

Área da saúde: Dermatologia

Resumo: Psoriasis treatment scenario has progressed rapidly over the last few decades; however, the use of immunobiologicals in immunocompromised individuals with psoriasis is rarely discussed in the literature.1 In transplant recipients, the potential risks of combining immunosuppressants with biological agents for the treatment of psoriasis are not fully known, as these patients are usually excluded from pivotal clinical trials.2 Immunocompromised patients, such as organ transplant recipients, require a careful risk-benefit assessment when selecting an immunobiological for the treatment of psoriasis.1 Due to the degree of immunosuppression necessary to prevent graft rejection, the acute form of the disease tends to disappear in the immediate period after the procedure. However, during the transition phase to a maintenance dose of immunosuppression, psoriasis may exacerbate. The transplant recipient body response can be influenced by the choice of immunosuppressive therapy, the transplanted organ, and individual tolerability.2 Currently, there are no guidelines for the treatment of moderate to severe psoriasis in transplant patients, and only a few case reports on the use of biologicals together with an immunosuppressive regimen have been described in the literature (Table 1).3 The authors report three cases of transplant patients receiving immunobiological agents for the treatment of psoriasis.

Envie um e-mail para os autores